Hair Regeneration in Menopausal and Androgenetic Alopecia Patients Using PTT-6®️ Exosomal Proteins
As seen in
Background:
Hair loss is a significant, yet often overlooked issue among menopausal women, with over 50% experiencing hair thinning or loss by age 50. The decline in estrogen and progesterone during menopause disrupts the hair cycle, leading to accelerated shedding and follicle miniaturisation, which impacts self-esteem and mental well-being. Existing treatments provide limited efficacy and potential side effects, highlighting the need for non-invasive, long-term solutions.
Objective:
To evaluate the efficacy and safety of PTT-6®️, a topical formulation of exosomal proteins derived from mesenchymal stem cells, in enhancing hair regeneration in women with menopausal hair loss and androgenetic alopecia.
Figure 1: Before.
Figure 2: After six weeks.
Figure 3: Before.
Figure 4: After 12 weeks.
Figure 5: Before.
Figure 6: After 12 weeks.
Figure 7: Before.
Figure 8: After 12 weeks.
Materials and Methods:
A total of 12 female participants aged 37 to 54, diagnosed with menopausal or androgenetic hair loss (Ludwig scale I–II), were enrolled in a clinical study at Time Clinic, London. Patients with active scalp diseases or recent use of hair growth medications were excluded. Each participant received a microneedling session, followed by five weeks of home treatment with a 0.5mm stamp and weekly PTT-6®️ application. Assessments were made at six and 12 weeks using digital photography, self-assessment questionnaires, and qualitative feedback regarding hair density, shedding reduction, and overall satisfaction.
Results:
At six weeks, 90% of participants reported noticeable improvements in hair shedding, thickness, and volume, particularly around the hairline and temples, with photographic documentation substantiating increased density. By week 12, all patients exhibited mild to significant improvement in hair growth and thickness, with no adverse events recorded.
Discussion:
The findings suggest that PTT-6®️ serves as a promising non-hormonal therapy for menopausal hair loss and androgenetic alopecia, stimulating follicular growth and density. Despite the small sample size and lack of objective measurements, subjective improvements indicate the need for further research with larger cohorts and controlled methodologies.
Conclusion:
PTT-6®️ exosomal protein application appears to be a viable, well-tolerated non-invasive option for women experiencing menopausal hair loss or androgenetic alopecia. The study supports its potential as a novel hair restoration strategy, warranting further investigation to establish standardized treatment protocols.
